By Dan Stanton+ 03-Feb-2015 Novo Nordisk will invest up to $760m in its manufacturing network in the coming year to support the growth of its insulin portfolio. Patented, Single-Pass TFF Revolutionizes Bioprocessing For 2015, capital expenditure at the Denmark-based biopharma firm is expected to be around DKK 5bn ($760m), CEO Jesper Brandgaard said in a conference ca..